GlassScriptPhysician profile
Franklin Mcgrew
NPI 1891979597
$2,975.18
in general payments reported to CMS, 2019-2025
31 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $779 · 2022: $1,058 · 2023: $890 · 2024: $132 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,138.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $591.01 | 2021-2024 | |
| Novo Nordisk INC | $248.70 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $191.80 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $171.34 | 2021-2023 | |
| Amgen INC. | $161.23 | 2021-2024 | Repatha, Otezla |
| Lilly USA, LLC | $155.07 | 2021-2023 | Jardiance, Trulicity, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.32 | 2021-2023 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $126.88 | 2022 | |
| Glaxosmithkline, LLC. | $120.61 | 2022-2023 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $117.87 | 2021-2022 | |
| Astellas Pharma US INC | $105.98 | 2021-2025 | Veozah |
| Dexcom, INC. | $105.54 | 2021-2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $75.92 | 2021-2022 | |
| Inspire Medical Systems, INC. | $67.27 | 2024-2025 | Inspire |
| Biohaven Pharmaceuticals, INC. | $64.32 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $57.93 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.27 | 2021 | |
| Ibsa Pharma INC. | $55.97 | 2022-2023 | Tirosint, Licart |
| Abiomed | $51.78 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.46 | 2022-2023 | Xifaxan, Trulance |
| Abbott Laboratories | $40.78 | 2022-2023 | Freestyle Libre 3 |
| Antares Pharma, INC. | $33.72 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Janssen Pharmaceuticals, INC | $31.66 | 2021-2022 | |
| Mylan Specialty L.P. | $21.83 | 2023 | Yupelri |
| Sumitomo Pharma America, INC. | $20.17 | 2023 | Gemtesa |
| Radius Health, INC. | $20.11 | 2022 | |
| Sunovion Pharmaceuticals INC. | $19.49 | 2022 | |
| Esperion Therapeutics, INC. | $19.36 | 2021 | |
| Seqirus USA INC | $18.54 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Eisai INC. | $17.73 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.52 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Franklin Mcgrew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.